Shares of Versartis Inc. (NASDAQ:VSAR) were up 5.6% on Friday . The stock traded as high as $10.69 and last traded at $10.60, with a volume of 135,342 shares trading hands. The stock had previously closed at $10.04.

Several analysts have weighed in on VSAR shares. Canaccord Genuity reiterated a “buy” rating on shares of Versartis in a research note on Monday, April 4th. Northland Securities started coverage on Versartis in a research note on Thursday, April 7th. They set an “outperform” rating on the stock. Zacks Investment Research upgraded Versartis from a “sell” rating to a “hold” rating in a research note on Tuesday, May 31st. Finally, Morgan Stanley reiterated a “hold” rating on shares of Versartis in a research note on Saturday, April 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Versartis currently has an average rating of “Hold” and a consensus price target of $17.20.

The company’s market cap is $311.94 million. The company has a 50 day moving average price of $10.33 and a 200 day moving average price of $9.38.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.